What’s Next? Five Things To Look Out For In February

Generics Bulletin previews the most noteworthy and anticipated events for February 2025.

What's Next Image
Source: Norstella

The floodgates are due to open for US biosimilar competition to Stelara (ustekinumab) in February, with a multitude of ustekinumab biosimilars that have received US Food and Drug Administration approval set to launch under the terms of patent-litigation settlement agreements.

Partners Alvotech and Teva – which gained approval for their Selarsdi (ustekinumab-aekn) version in April –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Preview

More from Biosimilars